Obesity induced cytokines and beta cell mass regulation

肥胖诱导的细胞因子和β细胞质量调节

• 批准号: 9211315
• 负责人: Amelia K Linnemann
• 金额: $ 16.3万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-04-01 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9211315
• 关键词: Adult; Affect; Alpha Cell; Apoptosis; Apoptotic; Beta Cell; Biological Assay; Biological Preservation; Cell Survival; Cell physiology; Cells; Cellular Stress; Cellular biology; Chemicals; Cholecystokinin; Clinical; Conflict (Psychology); Cytoprotection; Data; Development; Diabetes Mellitus; Diabetes prevention; Disease; Dose; Environment; Event; Future; GLP-I receptor; Genes; Genetic Transcription; Glucose; Goals; High Fat Diet; Hormones; In Vitro; Individual; Inflammation; Insulin Resistance; Interleukin 6 Receptor; Interleukin-6; Islet Cell; Islets of Langerhans; Knock-out; Knockout Mice; Knowledge; Literature; LoxP-flanked allele; Maintenance; Maps; Mediating; Mentors; Metabolic Pathway; Metabolism; Mollies; Mus; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Pathway interactions; Peripheral; Physiology; Prevalence; Production; Regulation; Research; Role; Scientist; Signal Transduction; Streptozocin; Stress; Structure of beta Cell of islet; Testing; Therapeutic Intervention; Thinness; Time; Training Programs; United States; Work; base; biological adaptation to stress; career; career development; cytokine; experience; glucagon-like peptide 1; in vivo; inflammatory marker; insulin secretion; insulin signaling; interest; interleukin-6 receptor alpha; islet; new therapeutic target; novel; prevent; programs; public health relevance; response; stressor; therapeutic target; transcriptome; transcriptome sequencing

 DESCRIPTION (provided by applicant): The goal of this application is to provide Dr. Linnemann with a comprehensive 5-year training program that will allow her to emerge as an independent academic scientist. Through this program she will gain valuable research experience in the fields of islet cell biology, in vivo physiology, obesity, and metabolic pathways Dr. Dawn Belt Davis and Dr. Michael MacDonald will serve as the primary co- mentors for her career and scientific development. Dr. Davis is an emerging leader in the field of diabetes and obesity research. Dr. MacDonald is an established leader in diabetes and metabolism and has a proven track record of mentoring both basic and clinical scientists. Dr. Linnemann has also assembled a mentoring committee comprised of outstanding scientists to provide the full spectrum of career development and scientific guidance. Her mentoring committee includes Dr. Vincent Cryns, Dr. Molly Carnes, and Dr. Michelle Kimple. The research plan involves the study of pancreatic beta cell protection from apoptosis in an obese environment. Obesity is associated with generalized inflammation and an increase in circulating cytokines such as interleukin-6 (IL-6). However, there is conflicting evidence as to the specific role of IL-6 in an obese state. Preliminary data suggests that circulating IL-6 initiates a cascade of intra-islet production of classic gut hormones, namely GLP-1 and cholecystokinin (CCK), that modulate beta cell survival and thus islet mass. Taking this into account, the central hypothesis is that obesity driven IL-6 stimulates adaptive stress response that promotes beta cell function and mass regulation. The specific aims of this application include 1) To determine how a multicomponent IL-6 driven pathway regulates beta cell survival; and 2) To define the in vivo role of IL-6 in obesity driven beta cell mass regulation. Together, these aims will allow the identification of a novel pathway in the protection of beta cells from apoptosis that may serve as a therapeutic target to aid in beta cell mass expansion.